Potassium Channel News and Research

RSS

ATP-sensitive potassium channel can contribute to fat deposition and obesity, new study says

A new study involving the University of Iowa, Mayo Clinic and two other institutions provides insight on weight control, suggesting that a ATP-sensitive potassium channel critical to survival and stress adaptation can contribute to fat deposition and obesity.

6 Jan 2010

Experimental drug to restore function of nerves damaged in spinal cord injuries shows promise

Researchers have shown how an experimental drug might restore the function of nerves damaged in spinal cord injuries by preventing short circuits caused when tiny "potassium channels" in the fibers are exposed.

20 Nov 2009

Recent data from CNSBio's Phase IIa CNSB015 trial to be presented at the Neuropathic Pain conference

CNSBio Inc. will present recent Phase IIa proof-of-concept clinical trial data for CNSB015, an orally administered potassium channel modulator used in combination with opioids for the treatment of neuropathic pain, at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain on November 20-21, 2009 in San Francisco, CA.

18 Nov 2009

Study reveals that KCNE2 and KCNQ1 mutations can results in thyroid dysfunction

Genes previously known to be essential to the coordinated, rhythmic electrical activity of cardiac muscle -- a healthy heartbeat -- have now also been found to play a key role in thyroid hormone (TH) biosynthesis, according to Weill Cornell Medical College researchers.

21 Sep 2009

NeuroMetrix completes private placement of common stock and warrants

NeuroMetrix, Inc., today announced that it has completed its private placement of common stock and warrants. Gross proceeds from the offering were approximately $18.7 million.

11 Sep 2009

NeuroMetrix to purchase $18.68 million of its common stock

NeuroMetrix, Inc., a healthcare company transforming patient care through neurotechnology, today announced that it has obtained commitments from institutional investors to purchase approximately $18.68 million of its common stock in a private placement.

9 Sep 2009

Retigabine's Phase IIa clinical trial preliminary results announced

Valeant Pharmaceuticals International today announced preliminary results from its Phase IIa proof-of-concept clinical trial of retigabine for the treatment of pain associated with postherpetic neuralgia (PHN), a painful and common complication of shingles.

24 Aug 2009

Study reveals high cholestrol as a cause of cardiac arrhythmias

Cholesterol can affect the flow of the electrical currents that generate the heart beat, according to a study from two UBC cardiovascular researchers funded by the Heart and Stroke Foundation of BC & Yukon. The research team has just published the important discovery about the causes of cardiac arrhythmias (abnormal heartbeats) in one of the world's leading scientific journals.

24 Aug 2009

Oxidation of potassium channel in cells linked to loss of neuronal function in aging

Researchers at UMDNJ-Robert Wood Johnson Medical School are one step closer to determining how human cells can be protected against the affects of age-related neurodegeneration including Alzheimer's and Parkinson's disease.

12 May 2009

Potential molecular target for new schizophrenia treatments

A study on schizophrenia has implicated machinery that maintains the flow of potassium in cells and revealed a potential molecular target for new treatments. Expression of a previously unknown form of a key such potassium channel was found to be 2.5 fold higher than normal in the brain memory hub of people with the chronic mental illness and linked to a hotspot of genetic variation.

5 May 2009

New anticonvulsant compound prevents seizure progression in model of epilepsy

Carnegie Mellon University researchers have identified a new anticonvulsant compound that has the potential to stop the development of epilepsy. The findings are published in the March issue of the journal Epilepsia.

4 May 2009

Search for blood pressure secrets reveals a surprising new syndrome

Yale researchers investigating the genetic causes of blood pressure variation have identified a previously undescribed syndrome associated with seizures, a lack of coordination, developmental delay and hearing loss.

16 Mar 2009

Century old drug clofazimine shows potential for multiple sclerosis

A century-old drug that failed in its original intent to treat tuberculosis but has worked well as an antileprosy medicine now holds new promise as a potential therapy for multiple sclerosis and other autoimmune diseases.

2 Feb 2009

Leconotide, an investigative calcium channel blocker, shows potential as pain treatment

Results of a pre-clinical study of leconotide, an investigative calcium channel blocker, shows it has the potential to be safe, selective, and efficacious as a new non-opioid treatment for pain relief. It also holds promise in multiple drug delivery options including nasal spray, transdermal patch, and pills. Data were presented today at the American Academy of Pain Medicine's 25th Annual Meeting.

29 Jan 2009

More scientific evidence supporting Darwinian views of evolution

Studies at the University of Pennsylvania School of Medicine on brain electrical signaling offer a fresh perspective on vertebrate evolution, provide additional evidence supporting Darwinian views of evolution, and may also lead to more effective treatment of epileptic seizures in infants.

21 Jan 2009